VICTOZA Drug Patent Profile
✉ Email this page to a colleague
When do Victoza patents expire, and what generic alternatives are available?
Victoza is a drug marketed by Novo Nordisk Inc and is included in one NDA. There are six patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and eighty-six patent family members in thirty-two countries.
The generic ingredient in VICTOZA is liraglutide recombinant. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the liraglutide recombinant profile page.
DrugPatentWatch® Generic Entry Outlook for Victoza
Victoza was eligible for patent challenges on January 25, 2014.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be February 13, 2026. This may change due to patent challenges or generic licensing.
Annual sales in 2019 were $5.6bn, indicating a strong incentive for generic entry.
There have been sixteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
Summary for VICTOZA
International Patents: | 186 |
US Patents: | 6 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 27 |
Clinical Trials: | 125 |
Patent Applications: | 3,742 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for VICTOZA |
Drug Sales Revenues: | Drug sales revenues for VICTOZA |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for VICTOZA |
What excipients (inactive ingredients) are in VICTOZA? | VICTOZA excipients list |
DailyMed Link: | VICTOZA at DailyMed |



DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VICTOZA
Generic Entry Date for VICTOZA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;SUBCUTANEOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for VICTOZA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Carmot Therapeutics, Inc. | Phase 1 |
Yale University | Phase 3 |
Chinese University of Hong Kong | Phase 1/Phase 2 |
Pharmacology for VICTOZA
Drug Class | GLP-1 Receptor Agonist |
Mechanism of Action | Glucagon-like Peptide-1 (GLP-1) Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for VICTOZA
Paragraph IV (Patent) Challenges for VICTOZA
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
VICTOZA | Injection | liraglutide recombinant | 18 mg/3 mL prefilled syringe | 022341 | 1 | 2016-12-12 |
US Patents and Regulatory Information for VICTOZA
VICTOZA is protected by six US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of VICTOZA is ⤷ Try a Trial.
This potential generic entry date is based on patent ⤷ Try a Trial.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting VICTOZA
Derivatives of GLP-1 analogs
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Needle mounting system and a method for mounting a needle assembly
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Needle mounting system and a method for mounting a needle assembly
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Injection button
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Liraglutide in cardiovascular conditions
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Expired US Patents for VICTOZA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
Novo Nordisk Inc | VICTOZA | liraglutide recombinant | SOLUTION;SUBCUTANEOUS | 022341-001 | Jan 25, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for VICTOZA
When does loss-of-exclusivity occur for VICTOZA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 04290862
Estimated Expiration: ⤷ Try a Trial
Brazil
Patent: 0416743
Estimated Expiration: ⤷ Try a Trial
Canada
Patent: 45034
Estimated Expiration: ⤷ Try a Trial
China
Patent: 82356
Estimated Expiration: ⤷ Try a Trial
Patent: 2784386
Estimated Expiration: ⤷ Try a Trial
Patent: 4826116
Estimated Expiration: ⤷ Try a Trial
Patent: 3304250
Estimated Expiration: ⤷ Try a Trial
Cyprus
Patent: 19723
Estimated Expiration: ⤷ Try a Trial
Denmark
Patent: 87019
Estimated Expiration: ⤷ Try a Trial
Patent: 00721
Estimated Expiration: ⤷ Try a Trial
European Patent Office
Patent: 87019
Estimated Expiration: ⤷ Try a Trial
Patent: 94656
Estimated Expiration: ⤷ Try a Trial
Patent: 00721
Estimated Expiration: ⤷ Try a Trial
Hong Kong
Patent: 46683
Estimated Expiration: ⤷ Try a Trial
Hungary
Patent: 38395
Estimated Expiration: ⤷ Try a Trial
Patent: 43210
Estimated Expiration: ⤷ Try a Trial
Japan
Patent: 58655
Estimated Expiration: ⤷ Try a Trial
Patent: 70373
Estimated Expiration: ⤷ Try a Trial
Patent: 07513084
Estimated Expiration: ⤷ Try a Trial
Patent: 12188424
Estimated Expiration: ⤷ Try a Trial
Mexico
Patent: 06005581
Estimated Expiration: ⤷ Try a Trial
Poland
Patent: 87019
Estimated Expiration: ⤷ Try a Trial
Patent: 00721
Estimated Expiration: ⤷ Try a Trial
Portugal
Patent: 87019
Estimated Expiration: ⤷ Try a Trial
Patent: 00721
Estimated Expiration: ⤷ Try a Trial
Russian Federation
Patent: 21238
Estimated Expiration: ⤷ Try a Trial
Patent: 06116414
Estimated Expiration: ⤷ Try a Trial
Slovenia
Patent: 87019
Estimated Expiration: ⤷ Try a Trial
Patent: 00721
Estimated Expiration: ⤷ Try a Trial
South Korea
Patent: 1243648
Estimated Expiration: ⤷ Try a Trial
Patent: 060100428
Estimated Expiration: ⤷ Try a Trial
Spain
Patent: 60320
Estimated Expiration: ⤷ Try a Trial
Patent: 27854
Estimated Expiration: ⤷ Try a Trial
Turkey
Patent: 1906789
Estimated Expiration: ⤷ Try a Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering VICTOZA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 1056774 | ⤷ Try a Trial | |
China | 1183975 | ⤷ Try a Trial | |
Portugal | 1687019 | ⤷ Try a Trial | |
Austria | 466026 | ⤷ Try a Trial | |
Russian Federation | 2421238 | ПЕПТИДНАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ПРОПИЛЕНГЛИКОЛЬ, ЯВЛЯЮЩАЯСЯ ОПТИМАЛЬНОЙ ДЛЯ ИЗГОТОВЛЕНИЯ И ПРИМЕНЕНИЯ В ИНЪЕКЦИОННЫХ УСТРОЙСТВАХ (PEPTIDE COMPOSITION CONTAINING PROPYLENE GLYCOL OPTIMAL FOR MANUFACTURING AND APPLICATION IN INJECTION DEVICES) | ⤷ Try a Trial |
Poland | 2109474 | ⤷ Try a Trial | |
China | 100502968 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for VICTOZA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0944648 | 09C0054 | France | ⤷ Try a Trial | PRODUCT NAME: LIRAGLUTIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/529/001 DU 20090630; REGISTRATION NO/DATE AT EEC: EU/1/09/529/001 DU 20090630 |
0944648 | C00944648/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: LIRAGLUTID; REGISTRATION NO/DATE: SWISSMEDIC 59329 11.12.2009 |
2209800 | SPC/GB14/079 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF, AND LIRAGLUTIDE, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF; REGISTERED: CH 65041 20140912; UK EU/1/14/947 20140922 |
0944648 | SPC034/2009 | Ireland | ⤷ Try a Trial | SPC034/2009: 20101001, EXPIRES: 20220821 |
2209800 | 14C0085 | France | ⤷ Try a Trial | PRODUCT NAME: LIRAGLUTIDE ET INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/14/947 20140918 |
2209800 | C300698 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: INSULINE DEGLUDEC EN LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/94765041 2014120918 |
2209800 | 122014000114 | Germany | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |